Aprogen Biologics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Aprogen Biologics has a total shareholder equity of ₩392.1B and total debt of ₩147.4B, which brings its debt-to-equity ratio to 37.6%. Its total assets and total liabilities are ₩610.8B and ₩218.7B respectively.
Belangrijke informatie
37.6%
Verhouding schuld/eigen vermogen
₩147.43b
Schuld
| Rente dekkingsratio | n/a |
| Contant | ₩23.64b |
| Aandelen | ₩392.09b |
| Totaal verplichtingen | ₩218.74b |
| Totaal activa | ₩610.83b |
Recente financiële gezondheidsupdates
Recent updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24Analyse van de financiële positie
Kortlopende schulden: A003060's short term assets (₩110.5B) do not cover its short term liabilities (₩155.5B).
Langlopende schulden: A003060's short term assets (₩110.5B) exceed its long term liabilities (₩63.2B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: A003060's net debt to equity ratio (31.6%) is considered satisfactory.
Schuld verminderen: A003060's debt to equity ratio has increased from 21.4% to 37.6% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: A003060 has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: A003060 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.